• Novo makes another early-stage diabetes bet with Ziylo buy evaluate
    August 21, 2018
    Intensifying pricing pressure in diabetes has not put Novo Nordisk off going after new technologies. The group’s latest acquisition, the UK company Ziylo, could lead to the development of insulin that “switches off” when blood glucose levels are too low.
PharmaSources Customer Service